We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Register for Free to get streaming real-time quotes, interactive charts, live options flow, and more.
| Name | Symbol | Market | Type |
|---|---|---|---|
| BioNTech SE | NASDAQ:BNTX | NASDAQ | Depository Receipt |
| Price Change | % Change | Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Traded | Last Trade | |
|---|---|---|---|---|---|---|---|---|---|---|
| 1.67 | 1.93% | 88.38 | 86.17 | 89.07 | 88.32 | 86.89 | 87.40 | 355,732 | 01:00:00 |
From Apr 2022 to Apr 2024
By Denny Jacob
BioNTech SE said Thursday that the European Medicines Agency granted priority medicines designation to BNT211, a potential treatment for third- or later-line testicular germ cell tumors.
The product candidate, which combines two approaches in one regimen, is currently being investigated in an ongoing Phase 1/2 study evaluating the safety and preliminary efficacy in heavily pretreated patients with relapsed or refractory advanced solid tumors, the company said.
The designation is based on positive preliminary Phase 1/2 data from the ongoing study, BioNTech said. The results showed that the treatment with CLDN6 CAR-T alone or in combination with CARVac, the company's two combined products, was well tolerated and showed positive signs of anti-tumor activity in testicular cancer patients at the first evaluated dose levels, the company said.
Write to Denny Jacob at denny.jacob@wsj.com
(END) Dow Jones Newswires
June 23, 2022 11:35 ET (15:35 GMT)
Copyright (c) 2022 Dow Jones & Company, Inc.
1 Year BioNTech Chart |
1 Month BioNTech Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Hot Features
Premium
